Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Horizon Pharma said its Swiss subsidiary and Mundipharma International Corporation and Mundipharma Medical Company have amended their exclusive distribution and supply agreements for commercialization of Lodotra in Asia to include Latin America.
Subscribe to our email newsletter
Lodotra is a proprietary, programmed-release formulation of low-dose prednisone and has received regulatory approval in Europe for the treatment of moderate to severe active rheumatoid arthritis (RA) when accompanied by morning stiffness.
The commercialization will happen in Mexico, Brazil, Argentina, Colombia, Venezuela, Peru, Chile, Ecuador, Dominican Republic, Guatemala, Costa Rica, Uruguay, Bolivia, Panama, Nicaragua, El Salvador and Honduras.
Mundipharma Asia Pacific & Latin America regional managing director Raman Singh said Lodotra represents an important advance in the improvement of outcomes and the quality of life for rheumatoid arthritis patients.
"We are excited about the addition of LODOTRA to our existing product portfolio in Latin America," Singh said.